3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
3
Phase 1
2
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Mature B-cell Neoplasms
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
257
Cyclophosphamide
241
Specimen Handling
198
fludarabine
173
Magnetic Resonance Spectroscopy
173
Biopsy
147
Nivolumab
119
Carboplatin
97
Radiotherapy
92
Paclitaxel
85
venetoclax
82
Cisplatin
80
Gemcitabine
79
fludarabine phosphate
78
Injections
68
Ipilimumab
64
Dexamethasone
61
atezolizumab
59
Bevacizumab
58
Cetuximab
57
Radiation
55
Fluorouracil
55
Azacitidine
55
durvalumab
54
Radiosurgery
52
Temozolomide
47
Rituximab
44
Oxaliplatin
44
Irinotecan
43
Docetaxel
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
ARQ531
×
1 year
×
Clear all
NCT05673460
2026-05-13
MK-1026-002
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
15 charts
NCT05347225
2026-04-30
MK-1026-005
Merck Sharp & Dohme LLC
Phase 1
Active not recruiting
12 enrolled